Evidence map›Paper›PMID 29246292›Full record

ArticleMolecular therapy. Nucleic acids2017

Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor.

Alexander Falkenhagen, Jastaranpreet Singh, Sabah Asad, Danila Leontyev, Stanley Read, Juan Carlos Zúñiga-Pflücker, Sadhna Joshi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Genetic Strategies for HIV Treatment and Prevention.Molecular therapy. Nucleic acids · 2018
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander FalkenhagenDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E2, Canada; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.
Jastaranpreet SinghDepartment of Immunology, University of Toronto, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada.
Sabah AsadDepartment of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Danila LeontyevDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E2, Canada.
Stanley ReadDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E2, Canada; Sunnybrook Research Institute, Toronto, ON, Canada.
Juan Carlos Zúñiga-PflückerDepartment of Immunology, University of Toronto, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada.
Sadhna JoshiDepartment of Molecular Genetics, University of Toronto, Toronto, ON M5S 3E2, Canada; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address: sadhna.joshi.sukhwal@utoronto.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV entry inhibitors are highly effective in controlling virus replication. We have developed a lentiviral vector that expresses a secreted entry inhibitor, soluble CD4 (sCD4), which binds to the HIV envelope glycoproteins and inactivates the virus. We have shown that sCD4 was secreted from gene-modified CD4

Indexed as

entry inhibitorgene therapyhematopoietic stem cellsHIVHIV entryhumanized miceNSG mouse modelpromotersoluble CD4T cells

Identifiers

PMID29246292
PMCPMC5633861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.